Genetic architecture of circulating very-long-chain (C24:0 and c22:0) ceramide concentrations

Sharon Cresci, Ruibo Zhang, Qiong Yang, Meredith S. Duncan, Vanessa Xanthakis, Xuntian Jiang, Ramachandran S. Vasan, Jean E. Schaffer, Linda R. Peterson

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Objective: Total ceramide concentrations are linked with increased insulin resistance and cardiac dysfunction. However, recent studies have demonstrated that plasma concentrations of specific very-long-chain fatty ceramides (C24:0 and C22:0) are associated with a reduced incidence of coronary heart disease and all-cause mortality. We hypothesized that specific genetic loci are associated with plasma C22:0 and C24:0 concentrations. Methods: Heritability and genome-wide association studies of plasma C24:0 and C22:0 ceramide concentrations were performed among 2,217 participants in the Framingham Heart Study Offspring Cohort, adjusting for cardiovascular risk factor covariates and cardiovascular drug treatment. Results: The multivariable-adjusted heritability for C22:0 and C24:0 ceramides was 0.42 (standard error [SE], 0.07; p=1.8E-9) and 0.25 (SE, 0.08; p=0.00025), respectively. Nineteen single nucleotide polymorphisms (SNPs), all on chromosome 20, significantly associated with C22:0 concentrations; the closest gene to these variants was SPTLC3. The lead SNP (rs4814175) significantly associated with 3% lower plasma C22:0 concentrations (p=2.83E-11). Nine SNPs, all on chromosome 20 and close to SPTLC3, were significantly associated with C24:0 ceramide concentrations. All 9 were also significantly related to plasma C22:0 levels. The lead SNP (rs168622) was significantly associated with 10% lower plasma C24:0 ceramide concentrations (p=9.94E-09). Conclusion: SNPs near the SPTLC3 gene, which encodes serine palmitoyltransferase long chain base subunit 3 (SPTLC3; part of the enzyme that catalyzes the rate-limiting step of de novo sphingolipid synthesis) were associated with plasma C22:0 and C24:0 ceramide concentrations. These results are biologically plausible and suggest that SPTLC3 may be a potential therapeutic target for C24:0 and C22:0 ceramide modulation.

Original languageEnglish
Pages (from-to)172-183
Number of pages12
JournalJournal of Lipid and Atherosclerosis
Issue number1
StatePublished - Jan 1 2020

Bibliographical note

Publisher Copyright:
© 2020 The Korean Society of Lipid and Atherosclerosis.


  • Cardiovascular disease
  • Genome-Wide Association Study
  • Genomics
  • Lipidomics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Genetic architecture of circulating very-long-chain (C24:0 and c22:0) ceramide concentrations'. Together they form a unique fingerprint.

Cite this